Investigation of women with endometrial carcinoma using serum vascular endothelial growth factor (VEGF) measurement

Gornall, R. J., Anthony, F. W., Coombes, E. J., Hogston, P. and Woolas, R. P. (2001) Investigation of women with endometrial carcinoma using serum vascular endothelial growth factor (VEGF) measurement. International Journal of Gynecological Cancer, 11 (2), 164-166. (doi:10.1046/j.1525-1438.2001.00097.x).

Abstract

Gornall RJ, Anthony FW, Coombs EJ, Hogston P, Woolas RP. Investigation of women with endometrial carcinoma using serum endothelial growth factor (VEGF) measurement.
This study assessed whether serum VEGF measurement in women presenting with endometrial cancer could predict advanced stage disease. Preoperative sera from 37 women undergoing laparotomy for suspected endometrial cancer were assayed for VEGF, CA125 and platelet count. Significant positive correlation was shown between VEGF and platelet levels (P = 0.003, r = 0.477). However, no correlation was demonstrated between VEGF and stage overall, and no significant difference was shown between those with early (stage 1A/1B, n = 20) compared to those with advanced (stage >1B, n = 13) or disseminated (stage >2, n = 7) disease. Serum VEGF measurement was not beneficial in the preoperative assessment of stage in patients with endometrial carcinoma. Strong correlation with platelet levels suggests that this is one of the sources of VEGF measured.

This record has no associated files available for download.

Contributors

Download statistics